ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 666 for:    Recruiting, Not yet recruiting, Available Studies | "Insulins"

Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03584607
Recruitment Status : Recruiting
First Posted : July 12, 2018
Last Update Posted : July 12, 2018
Sponsor:
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:
Insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension. In this pilot study, the investigators´ goal is to directly determine insulin sensitivity in idiopathic pulmonary arterial hypertension patients and to compare the results with data from healthy controls.

Condition or disease
Insulin Resistance

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension - a Pilot Study
Actual Study Start Date : December 20, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019


Group/Cohort
Idiopathic Pulmonary Arterial Hypertension patients
Blood sampling Insulin resistance-measurement
Healthy controls
Blood sampling Insulin resistance-measurement



Primary Outcome Measures :
  1. Insulin resistance [ Time Frame: 1 day ]
    Determination of insulin sensitivity using hyperinsulinemic-euglycemic clamp technique



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy controls, or patients with idiopathic or hereditary pulmonary hypertension
Criteria

Inclusion Criteria:

  • signed informed consent form
  • patients with idiopathic or hereditary pulmonary hypertension / healthy controls

Exclusion Criteria:

  • premenopausal women
  • other relevant lung disease
  • relevant left heart disease
  • untreated systemic hypertension
  • Diabetes mellitus
  • pulmonary hypertension other than idiopathic or hereditary form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03584607


Contacts
Contact: Horst Olschewski, MD +43 (316) 385 12183 horst.olschewski@medunigraz.at
Contact: Gabor Kovacs, MD +43 (316) 385 12183 Gabor.Kovacs@klinikum-graz.at

Locations
Austria
Medical University Graz, Division of Pulmonology Recruiting
Graz, Steiermark, Austria, 8010
Contact: Horst Olschewski, MD    +43 (316) 385 12183    horst.olschewski@medunigraz.at   
Contact: Gabor Kovacs, MD    +43 (316) 385 12183    gabor.kovacs@klinikum-graz.at   
Principal Investigator: Bence M. Nagy, PhD         
Sponsors and Collaborators
Medical University of Graz
Investigators
Principal Investigator: Bence M. Nagy, PhD Medical University of Graz

Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT03584607     History of Changes
Other Study ID Numbers: 29-066 ex 16/17
First Posted: July 12, 2018    Key Record Dates
Last Update Posted: July 12, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Insulin Resistance
Hypertension
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Insulin, Globin Zinc
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs